Karyopharm Therapeutics (NASDAQ:KPTI) provided new and updated data from its Phase 1b/2 study evaluating selinexor and dexamethasone in combination with standard approved multiple myeloma (MM) therapies.
Selinexor is a nuclear export compound that causes the accumulation of tumor suppressor proteins in the cell nucleus, inducing apoptosis in cancer cells.
Oral, once weekly administration of selinexor combined with low dose dexamethasone demonstrated a 78%, 73% and 57% overall response rate when combined with carfilzomib, daratumumab and pomalidomide, respectively.
“Preliminary data from the [carfilzomib] arm of the Phase 1b/2 study show early but encouraging clinical activity, including two patients who achieved a complete response, along with an expected and manageable tolerability profile, in patients with heavily pretreated, double-refractory [carfilzomib]-naïve multiple myeloma,” Sharon Shacham, Karopharm’s president and CSO, said in a statement.
Selinexor’s NDA is currently under priority review with a PDUFA action date of July 6, 2019.
